Form 4: Repare Therapeutics CEO Lloyd Mitchell Segal Reports Acquisition of Stock Options and Restricted Stock Units

Lloyd Mitchell Segal, President and CEO of Repare Therapeutics Inc., reports the acquisition of stock options and restricted stock units, along with transactions in common shares.

Summary

• On March 4, 2025, Lloyd Mitchell Segal, the President and CEO of Repare Therapeutics Inc., reported transactions involving the company's securities.
• Segal acquired 40,000 common shares through a restricted stock unit (RSU) award, with vesting occurring in three equal installments on March 4, 2026, March 4, 2027, and March 4, 2028, contingent upon continued service.
• He also acquired 237,000 shares through an employee stock option with an exercise price of $1.17, vesting 25% on March 4, 2026, and the remainder monthly thereafter, also contingent upon continued service.
• Additionally, Segal reported owning 145,573 common shares directly and 107,558 common shares indirectly through Arvala Inc., where he is the sole stockholder.
• The report includes shares acquired under the Issuer's employee stock purchase plan on August 15, 2024 (895 shares) and February 15, 2025 (2,000 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing insider transactions, which doesn't inherently indicate positive or negative sentiment. The acquisitions suggest confidence, but it's a routine disclosure.

Positives

• The acquisition of RSUs and stock options by the CEO demonstrates confidence in the company's future performance.
• The vesting schedules for the RSUs and stock options incentivize the CEO to remain with the company and contribute to its long-term success.
• Participation in the employee stock purchase plan indicates a belief in the company's value and growth potential.

Risks

• The value of the acquired shares and options is subject to market fluctuations and the company's performance.
• The vesting of the RSUs and stock options is contingent upon the CEO's continued service, creating a potential risk if he were to leave the company before the vesting dates.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in the biotechnology industry.
• Vesting schedules are typically structured to align executive incentives with long-term company performance, similar to practices at companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
• Employee stock purchase plans are also common, allowing employees to acquire company stock at a discounted rate, aligning their interests with shareholders.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they indicate the CEO's confidence in the company.
• Employees participating in the stock purchase plan benefit from the opportunity to acquire company stock at a discounted rate.

Key Dates